BACKGROUND: Regimen selection for highly treatment-experienced patients is complicated. METHODS: Using a web-based utility, study team members reviewed antiretroviral (ARV) history and resistance data and recommended individual ARV regimens and nucleoside reverse transcriptase inhibitor (NRTI) options for treatment-experienced participants consisting of 3-4 of the following agents: raltegravir (RAL), darunavir (DRV)/ritonavir, tipranavir (TPV)/ritonavir, etravirine (ETR), maraviroc (MVC), and enfuvirtide (ENF). We evaluated team recommendations and site selection of regimen and NRTIs. Associations between baseline factors and the selection of a complex regimen (defined as including four ARV agents or ENF) were explored with logistic regression. RESULTS: A total of 413 participants entered the study. Participants initiated the first or second recommended regimen 86% of the time and 21% of participants started a complex regimen. In a multivariable model, ARV resistance to NRTI (odds ratio [OR] = 2.2), non-nucleoside reverse transcriptase inhibitor (NNRTI, OR = 6.2) or boosted protease inhibitor (PI, OR = 6.6), prior use of integrase strand transfer inhibitor (INSTI, OR = 25), and race-ethnicity (all P ≤ 0.01) were associated with selection of a complex regimen. Black non-Hispanic (OR = 0.5) and Hispanic participants from the continental US (OR = 0.2) were less likely to start a complex regimen, compared to white non-Hispanics. CONCLUSIONS: In this multi-center trial, we developed a web-based utility that facilitated treatment recommendations for highly treatment-experienced patients. Drug resistance, prior INSTI use, and race-ethnicity were key factors in decisions to select a more complex regimen.
BACKGROUND: Regimen selection for highly treatment-experienced patients is complicated. METHODS: Using a web-based utility, study team members reviewed antiretroviral (ARV) history and resistance data and recommended individual ARV regimens and nucleoside reverse transcriptase inhibitor (NRTI) options for treatment-experienced participants consisting of 3-4 of the following agents: raltegravir (RAL), darunavir (DRV)/ritonavir, tipranavir (TPV)/ritonavir, etravirine (ETR), maraviroc (MVC), and enfuvirtide (ENF). We evaluated team recommendations and site selection of regimen and NRTIs. Associations between baseline factors and the selection of a complex regimen (defined as including four ARV agents or ENF) were explored with logistic regression. RESULTS: A total of 413 participants entered the study. Participants initiated the first or second recommended regimen 86% of the time and 21% of participants started a complex regimen. In a multivariable model, ARV resistance to NRTI (odds ratio [OR] = 2.2), non-nucleoside reverse transcriptase inhibitor (NNRTI, OR = 6.2) or boosted protease inhibitor (PI, OR = 6.6), prior use of integrase strand transfer inhibitor (INSTI, OR = 25), and race-ethnicity (all P ≤ 0.01) were associated with selection of a complex regimen. Black non-Hispanic (OR = 0.5) and Hispanic participants from the continental US (OR = 0.2) were less likely to start a complex regimen, compared to white non-Hispanics. CONCLUSIONS: In this multi-center trial, we developed a web-based utility that facilitated treatment recommendations for highly treatment-experienced patients. Drug resistance, prior INSTI use, and race-ethnicity were key factors in decisions to select a more complex regimen.
Entities:
Keywords:
Antiretroviral therapy; HIV drug resistance,; Phenotypic susceptibility score,; Treatment-experienced,; Tropism,; cPSS,
Authors: David A Katzenstein; Ronald J Bosch; Nicholas Hellmann; Nan Wang; Lee Bacheler; Mary A Albrecht Journal: AIDS Date: 2003-04-11 Impact factor: 4.177
Authors: Thomas B Campbell; Nancy S Shulman; Steven C Johnson; Andrew R Zolopa; Russell K Young; Lane Bushman; Courtney V Fletcher; E Randall Lanier; Thomas C Merigan; Daniel R Kuritzkes Journal: Clin Infect Dis Date: 2005-06-07 Impact factor: 9.079
Authors: Zoe Fox; Ulrik B Dragsted; Jan Gerstoft; Andrew N Phillips; Jesper Kjaer; Lars Mathiesen; Mike Youle; Christine Katlama; Andrew Hill; Johan N Bruun; Nathan Clumeck; Pierre Dellamonica; Jens D Lundgren Journal: Antivir Ther Date: 2006
Authors: Ronald Swanstrom; Ronald J Bosch; David Katzenstein; Hailong Cheng; Hongyu Jiang; Nicholas Hellmann; Richard Haubrich; Susan A Fiscus; Courtney V Fletcher; Edward P Acosta; Roy M Gulick Journal: J Infect Dis Date: 2004-07-23 Impact factor: 5.226
Authors: Jacob P Lalezari; Keith Henry; Mary O'Hearn; Julio S G Montaner; Peter J Piliero; Benôit Trottier; Sharon Walmsley; Calvin Cohen; Daniel R Kuritzkes; Joseph J Eron; Jain Chung; Ralph DeMasi; Lucille Donatacci; Claude Drobnes; John Delehanty; Miklos Salgo Journal: N Engl J Med Date: 2003-03-13 Impact factor: 91.245
Authors: Karen T Tashima; Laura M Smeaton; Carl J Fichtenbaum; Adriana Andrade; Joseph J Eron; Rajesh T Gandhi; Victoria A Johnson; Karin L Klingman; Justin Ritz; Sally Hodder; Jorge L Santana; Timothy Wilkin; Richard H Haubrich Journal: Ann Intern Med Date: 2015-11-24 Impact factor: 25.391
Authors: Rajesh T Gandhi; Karen T Tashima; Laura M Smeaton; Vincent Vu; Justin Ritz; Adriana Andrade; Joseph J Eron; Evelyn Hogg; Carl J Fichtenbaum Journal: J Infect Dis Date: 2020-04-07 Impact factor: 7.759
Authors: Sharon Valenti; Leonard Johnson; Susan Szpunar; Raymond Hilu; Louis Saravolatz Journal: Open Forum Infect Dis Date: 2019-02-27 Impact factor: 3.835
Authors: Amedeo F Capetti; Maria Vittoria Cossu; Giancarlo Orofino; Gaetana Sterrantino; Giovanni Cenderello; Giuseppe V De Socio; Anna Maria Cattelan; Alessandro Soria; Stefano Rusconi; Niccolò Riccardi; Gian Maria Baldin; Fosca P Niero; Giorgio Barbarini; Giuliano Rizzardini Journal: BMC Infect Dis Date: 2017-09-30 Impact factor: 3.090